

What the New Administration and Congress Mean for Health Plans and PBMs

November 13, 2024





## **Today's Speakers**



Rachel Alexander

Member

Mintz

RAlexander@mintz.com



Theresa Carnegie

Member

Mintz

TCCarnegie@mintz.com



Alex Hecht

Executive Vice President &

Director of Operations

ML Strategies

AHecht@mlstrategies.com



## **Top-Line 2024 Election Takeaways....**



- Trump wins electoral college 312 votes
- Trump wins the popular vote (unlike 2016)
- US Senate flips to GOP control
  - 3 seat majority
- GOP likely to maintain control of U.S. House
  - slim majority

# **GOP Assumes Control over Executive and Legislative Branches**



#### What Does It All Mean?





#### 2024 Election: Health Care Issues

- During the campaign, Former President Trump, Vice President Harris, and Congressional Leadership did not call for the significant heath care reforms that we've seen in recent elections
  - No pledges to "repeal and replace" the ACA or transition the private insurance market to a "Medicare for All" single-payer framework
- Instead, the incoming Trump administration and the GOP-controlled Congress will focus on a range of health care issues, including:
  - Potential modifications to the Affordable Care Act (ACA);
  - Medicare (including the new Medicare drug price negotiation program);
  - Medicaid reform;
  - Pharmacy benefit manager (PBM) reform; and
  - Market-based health insurance reforms



## **Health Care Priorities – 119th Congress**

#### Republican Leadership

- Trim down the ACA
- Reduce spending on Medicaid
  - Institute "block grants", work requirements, and eligibility limits
- PBM oversight and reform
- Market-Based Approaches:
  - HSA/HDHP Enhancement
  - High Risk Pools
  - Association Health Plans (AHPs)

#### **Democratic Leadership**

- Protect the ACA, Medicaid, and Medicare
- Address the maternal health crisis
- PBM oversight and reform
- Restore Roe's protections for reproductive rights
- Increase health care access and equity
- Continued scrutiny on private equity



## **President Trump on Health Care**

- Modify the ACA, instead of repealing and replacing it
  - Eliminate ACA marketplace subsidies and cut funding for outreach efforts
- Potential large scale Medicaid changes
  - Work requirements for Medicaid eligibility, Medicaid block grant funding, and the end of the ACA's Medicaid expansion
- Keep in place the IRA's price negotiation program, but push for smaller price reductions
- Leave reproductive rights to the states





## **Key Potential Players – Trump Administration**



Robert Kennedy Jr.

– Announced Nominee to oversee Department of Health and Human Services



Dr. Mehmet OzAnnounced Nominee to lead the Centers for Medicare & Medicaid Services





## **Key Congressional Potential Health Players**

#### **Senate**

#### **HELP Committee**



Sen. Cassidy (R-LA)



Sen. Sanders (I-VT)

#### **Finance Committee**



Sen. Crapo (R-ID)



Sen. Wyden (D-OR)

#### House

#### **E&C Committee**



Rep. Latta (R-OH5)



Rep. Guthrie (R-KY2)



Rep. Pallone (D-NJ6)

#### **Ways & Means Committee**



Rep. Smith (R-MO8)



Rep. Neal (D-MA1)



#### What to Look Out For on The Hill: Health Care

#### The ACA, Medicaid, and Medicare

Legislation to modify these programs

#### **House GOP Priorities**

- Reduce federal health care bureaucracy
- Medicaid reform
- Reform IRA drug price-setting
- Expanding rural access to health care
- Market-based health insurance reforms

#### Senate GOP Priorities

- PBM reform
- Medicaid reform
- Market-based health insurance reforms
- Social Security Bipartisan Working Group....



## **PBM Reform: Potential Bipartisan Priorities**

# **Banning Spread Pricing and Implementing Delinking Policies**


- The Senate's Modernizing and Ensuring PBM Accountability Act, voted 26-1 out of Committee, would delink PBM compensation from the price of a drug in Medicare Part D and prohibit spread pricing in Medicare
- The Lower Costs, More
   Transparency Act, passed by the
   House, would prohibit PBMs from
   spread pricing in Medicaid and
   require semi-annual reports from
   PBMs on drug costs, rebates, and
   formulary placement rationale

# **Increasing Transparency and Ensuring Accountability**

- The PBM Transparency Act, which advanced to the full Senate by a 18-9 vote, would require that PBMs disclose information about rebates, including the amount passed through the plan sponsor, to the FTC
- The same Act also expressly authorizes the FTC to crack down on unfair or deceptive conduct committed by PBMs



#### What to Look Out For in Administration




# Traditional Republicans

- Pro-Business
- Anti-Regulation
  - Lower Taxes


#### **Populist Wing**

- Distrustful of Government Institutions
- Blame Large Corporations (e.g., Pharma, Food Industry) for Poor US Health





## **Administration Impact - Pharma**



Phurma
Phurma
Make America Healthy Again
Ban Pharmaceutical Ads:
SIGN THE PETITION

- IRA Modification but no wholesale repeal
- FTC Positive for Pharma M&A
- Drug Ads 1<sup>st</sup> Amendment obstacles
- Vaccines Manufacturer liability protections
- March-in Rights Off the Table
- PBMs Legislative Focus Shift

## The Bayh-Dole Act



FTC Sues to Block Biopharmaceutical Giant Amgen from Acquisition That Would Entrench Monopoly Drugs Used to Treat Two Serious Illnesses

The \$27.8 billion acquisition of Horizon Therapeutics plc would enable Amgen Inc. to stifle competition for thyroid eye disease and chronic refractory gout treatments, the agency says



## **Administration Impact - Insurers**

# Affordable Care Act

- No repeal
- End to Enhanced Subsidies
- Potential loss of ACA lives – higher uninsured rate
- Negative for ACA plan sponsors

#### Medicaid

- Likely to face cuts
- 41 states use private insurers to run Medicaid programs
- Loss of revenue for insurers administering Medicaid Managed Care Plans

## Medicare Advantage

- Typically favored by Republicans
- Recent allegations that overpaid
- Biden Reforms (payment cuts, audits)
- Targeted Fixes and Improvements?



## Administration Impact – PBMs, M&A, FDA, Etc.

#### PBM Regulation and Legislation

- Continued FTC Scrutiny?
- Federal Legislation?

#### Market Expects M&A Activity to Open Up Under Trump

 Slow deal-making due to high interest rates, exorbitant valuations, difficult regulatory environment – PE scrutiny, FTC enforcement

#### FDA

- RFK Influence?
  - Fluoride in water, Processed Foods, Vaccines

#### Women's Reproductive Health

- Abortion rights left to the states
- Access to Medication, Fertility Services, IVF









## What to Expect in Lame Duck Session



"Lame Duck" Congressional Session



Potential health-related provisions in play:

Medicare telehealth flexibilities Medicare payment extenders Legacy bills



Potential upcoming vehicles?

End of Year Omnibus? Tax Reform Legislation Spring 2025



# Questions?